

Delineation and Classifications of Adverse Drug Reaction: Brief Communication

Gudisa Bereda

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia

Email address:

gudisabareda95@gmail.com

To cite this article:

Gudisa Bereda. Delineation and Classifications of Adverse Drug Reaction: Brief Communication. *International Journal of Pharmacy and Chemistry*. Vol. 7, No. 6, 2021, pp. 122-124. doi: 10.11648/j.ijpc.20210706.13

Received: December 7, 2021; **Accepted:** December 30, 2021; **Published:** December 31, 2021

Abstract: Adverse drug reaction defined as reaction to medicine which is noxious and unintended and occurs at doses of medications normally used for prophylaxis, diagnosis, or treatment of disease or to change physiologic functions. Serious adverse effect defined as any unfavorable medical incidence that happens at any dose and results in death necessitates hospital admission or prolonged hospital stay, results in continuity or indispensable disability, or is life threatening. Type “A” adverse drug reaction is greatly happened and solely causes low mortality, and also treated by adjusting dose of the medication; for example toxic effects of alpha-adrenergic blockage side effects that is associated with tricyclic antidepressants; sexual dysfunction of selective serotonin reuptake inhibitors; ototoxicity from aminoglycosides toxicity; serotonin syndrome of monoamine oxidase inhibitors. Type “B” reactions signifies ‘(bizarre, idiosyncratic), unpredictable or non-pharmacological, frequently allergic, response reactions are novel responses that are not anticipated from the familiar pharmacological actions of the medication. Type “C” reactions signifies ‘continuing or long term (time related)’ reactions, continue for a relatively long time and prolonged usage of medicine. Type “D” reactions signifies ‘delayed (lag time)’ reactions, becomes presumed occasionally after the usage of a medication. Type “E” reactions signifies ‘ending-of-usage (withdrawal)’ reactions, is associated with the withdrawal of a medication. For example is withdrawal syndrome with benzodiazepines; withdrawal syndrome with tricyclic antidepressants and the undesired effects of ceasing the drug (for example, rebound hypertension with beta blockers). Type “F” reactions signifies ‘unanticipated failure of therapy (no response). Where a medication unpleasantly escalates or de-escalates in efficacy, for examples, the de-escalated clearance of a medication by dialysis, or the de-escalated consequence of antimicrobials agents’ particularly anti-tuberculosis medication resistance due to resistant organism.

Keywords: Adverse Drug Reaction, Classifications, Delineation

1. Introduction

Lack of a method for checking drug safety is a considerable challenge giving to meager wholeness in Ethiopia and distinctive sub Saharan countries. While ultimatum for medications is escalating, comparable measurements to guarantee their safety are absent [1-7]. Adverse drug reaction perhaps delineated as ‘any response to a medicine which is noxious, unintended and happens at doses normally used for prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function’. Adverse drug reactions are consequently unwanted or unintended effects of a medication, enclosing idiosyncratic effects, which happen during its correct usage. They vary from unintentional or intentional over dosage or medicine

erroneously [8-10]. The probability of Adverse drug events happening perhaps also escalate during changes of meticulousity (e.g., release from a hospital to their home or long suffering’ replace from one health care provider or setting to distinctive), when information perhaps not sufficiently transformed between health care providers [11, 12] or patient perhaps not comprehensively conclude how to address their medicines. Side effect delineated as any unintended consequence of a medicinal product happening at normal therapeutic doses and is related to its pharmacological properties. Such outcomes perhaps prominent and even anticipated and necessitate small or no revamp in patient guidance [13]. Serious adverse effect delineated as any unfavorable medical incidence that happens at any dose and results in death necessitates hospital admission or prolonged

hospital stay, results in continuity or indispensable disability, or is life threatening. Adverse drug reaction delineated as reaction to medicine which is noxious and unintended and occurs at doses of medications normally used for prophylaxis, diagnosis, or treatment of disease or to change physiologic functions. Adverse drug events (ADEs) enclose medicine errors and overdoses [14-16].

2. Classification of ADRs According to Mechanism of Origin

Adverse drug reaction (ADRs) classified as below: (1) Type "A" reactions signifies' (intrinsic, augmented), predictable, dose-related or exaggerated pharmacological response reactions result from an elaboration of a medication's usual pharmacological actions when given at the normal medicinal dose and are regularly dose-dependent; instances pharmacodynamics consequences of bronchoconstriction of non-selective beta blockers; respiratory depression with aesthetics agents, bleeding with non-steroidal anti-inflammatory drugs, optic neuritis of ethambutol. Type A reactions also enclose those that are not directly related to the desired pharmacological action of the medication related to dosage, for example toxic effects of alpha-adrenergic blockage side effects that is associated with tricyclic antidepressants; sexual dysfunction of selective serotonin reuptake inhibitors; ototoxicity from aminoglycosides toxicity; serotonin syndrome of monoamine oxidase inhibitors. Type "A" Adverse drug reaction is greatly happened and solely causes low mortality, and also treated by adjusting dose of the medication [17, 18]. (2) Type "B" reactions signifies' (bizarre, idiosyncratic), unpredictable or non-pharmacological, frequently allergic, response reactions are novel responses that are not anticipated from the familiar pharmacological actions of the medication. These are lower most, and so perhaps only find out for the 1st time after a medicine has already been made accessible for universal usage and enclose allergic reactions; examples anaphylaxis with penicillin or skin rashes with non-nucleoside reverse transcriptase inhibitors, and idiosyncratic reactions; instances bone marrow suppression of chloramphenicol; heparin induced thrombocytopenia. Type "B" Adverse drug reaction is slightly happened and cause great mortality, and also treated by stopping the administered medication [19, 20]. (3) Type "C" reactions signifies' 'continuing or long term (time related)' reactions, continue for a relatively long time and prolonged usage of medicine [21]. For example is osteonecrosis of the jaw with bisphosphonates and osteoporosis of oral steroids. (4) Type "D" reactions signifies' delayed (lag time)' reactions, becomes presumed occasionally after the usage of a medication. The timing of these perhaps makes them further challenge to ascertain. For example is teratogenic effects of angiotensinogen converting enzyme inhibitors during second and third trimester and prolonged usage in a medicine which doesn't tend to concentrate (eg. extrapyramidal symptoms such as tardive dyskinesia of antipsychotics (haloperidol deconate) [22, 23]. (5) Type "E"

reactions signifies' 'ending-of-usage (withdrawal)' reactions, is associated with the withdrawal of a medication. For example is withdrawal syndrome with benzodiazepines; withdrawal syndrome with tricyclic antidepressants and the undesired effects of stopping the drug (for example, rebound hypertension with beta blockers) [24]. (6) Type "F" reactions signifies' unanticipated failure of therapy (no response). Where a medication unpleasantly escalates or de-escalates in efficacy, for instances, the de-escalated clearance of a medication by dialysis, or the de-escalated consequence of antimicrobials agents' particularly anti-tuberculosis medication resistance due to resistant organism [25].

3. Conclusion

Adverse drug reaction delineated as reaction to medicine which is noxious and unintended and occurs at doses of medications normally used for prophylaxis, diagnosis, or treatment of disease or to change physiologic functions. Adverse drug events enclose medicine errors and overdoses. Type "A" reactions signifies' (intrinsic, augmented), predictable, dose-related or exaggerated pharmacological response reactions result from an elaboration of a medication's usual pharmacological actions when given at the normal medicinal dose and are regularly dose-dependent; examples pharmacodynamics consequences of bronchoconstriction of non-selective beta blockers; respiratory depression with aesthetics agents, bleeding with non-steroidal anti-inflammatory drugs, optic neuritis of ethambutol. Type "B" reactions signifies' (bizarre, idiosyncratic), unpredictable or non-pharmacological, frequently allergic, response reactions are novel responses that are not anticipated from the familiar pharmacological actions of the medication. Type "C" reactions signifies' 'continuing or long term (time related)' reactions, continue for a relatively long time and prolonged usage of medicine. Type "D" reactions signifies' delayed (lag time)' reactions, becomes presumed occasionally after the usage of a medication. The timing of these perhaps makes them further challenge to ascertain. For example teratogenic effects of angiotensinogen converting enzyme inhibitors during second and third trimester and prolonged usage in a medicine which doesn't tend to concentrate (eg. extrapyramidal symptoms such as tardive dyskinesia of antipsychotics (haloperidol deconate). Type "E" reactions signifies' 'ending-of-usage (withdrawal)' reactions, is consociated with the withdrawal of a medication. Type "F" reactions signifies' unanticipated failure of therapy (no response). Where a medication unpleasantly escalates or de-escalates in efficacy, for instances, the de-escalated clearance of a medication by dialysis, or the de-escalated consequence of antimicrobials agents' particularly anti-tuberculosis medication resistance due to resistant organism.

Acknowledgements

The author acknowledged those all who support him during preparation of this manuscript.

References

- [1] Atif M, Malik I, Asif M, Qamar-Uz-Zaman M, Ahmad N, Scahill S. Drug safety in Pakistan. In *Drug Safety in Developing Countries* 2020 Jan 1 (pp. 287-325). Academic Press.
- [2] Agyepong IA, Sewankambo N, Binagwaho A, Coll-Seck AM, Corrah T, Ezech A, Fekadu A, Kilonzo N, Lamptey P, Masiye F, Mayosi B. The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa. *The Lancet*. 2017 Dec 23; 390 (10114): 2803-59.
- [3] S. Hanafi, H. Torkamandi, A. Hayatshahi, K. Gholami, and M. Javadi, "Knowledge, attitudes and practice of nurse regarding adverse drug reaction reporting," *Iranian Journal of Nursing and Midwifery Research*, vol. 17, no. 1, pp. 21–25, 2012.
- [4] World Health Organization, WHO Guide Lines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, World Health Organization, 2004, July 2020, <https://apps.who.int/iris/handle/10665/43034>.
- [5] Organization WH, The Selection of Essential Medicines, World Health Organization, 2002, July 2020, https://apps.who.int/iris/bitstream/handle/10665/67375/WHO_EDM_2002.2_eng.pdf.
- [6] Y. Ji, H. Ying, P. Dews et al., "A potential causal association mining algorithm for screening adverse drug reactions in postmarketing surveillance," *IEEE Transactions on Information Technology in Biomedicine*, vol. 15, no. 3, pp. 428–437, 2011.
- [7] R. A. Kamtane and V. Jayawardhani, "Knowledge, attitude and perception of physicians towards adverse drug reaction (ADR) reporting: a pharmacoepidemiological study," *Asian Journal of Pharmaceutical and Clinical Research*, vol. 5, no. 3, pp. 210–214, 2012.
- [8] Ajantha HB, Kumar MP. Knowledge, attitude, and practices regarding adverse drug reaction reporting among dental students. *Drug Invention Today*. 2018 Jun 1; 10 (6).
- [9] M. R. Hodgkinson, N. J. Dimbauer, and I. Larmour, "Identification of adverse drug reactions using the ICD-10 Australian modification clinical coding surveillance," *Journal of Pharmacy Practice and Research*, vol. 39, no. 1, pp. 19–23, 2009.
- [10] G. T. Tegegne, T. Gaddisa, B. Kefale, G. Tesfaye, and J. Likisa, Drug Therapy Problem and Contributing Factors among Ambulatory Hypertensive Patients in Ambo General Hospital, *Global Journal of Medical Research*, West Shoa, Ethiopia, 2015.
- [11] McGee C. A Receiver Lacks Standing to Recover Fraudulent Transfers under UFTA when Corporation has not been Adequately Cleansed from Fraudulent Actions of Ponzi Schemers.
- [12] FMHACA, Guideline for Adverse Drug Events Monitoring (Pharmacovigilance), Food, Medicine and Health Care Administration and Control Authority of Ethiopia, 3rd edition, 2014, July 2020, <https://www.medbox.org/document/guideline-foradverse-drug-events-monitoring-pharmacovigilance-ethiopia>.
- [13] Wang CS, Lin PJ, Cheng CL, Tai SH, Yang YH, Chiang JH. Detecting potential adverse drug reactions using a deep neural network model. *Journal of medical Internet research*. 2019; 21 (2): e11016.
- [14] Haerian K, Varn D, Vaidya S, Ena L, Chase HS, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. *Clin Pharmacol Ther*. 2012; 92 (2): 228–34.
- [15] Lobo MG, Pinheiro SM, Castro JG, Momenté VG, Pranchevicius MC. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. *BMC Pharmacol Toxicol*. 2013; 14 (1): 5.
- [16] Cutroneo PM, Polimeni G. Adverse Drug Reactions: Definitions, Classifications and Regulatory Aspects. In *Pharmacovigilance in Psychiatry* 2016 (pp. 9-25). Adis, Cham.
- [17] Tridente G. Adverse drug events to biomedicines. In *Adverse Events with Biomedicines* 2014 (pp. 15-24). Springer, Milano.
- [18] Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. *Ann Rheum Dis*. 2008; 67 (2): 189–94.
- [19] Hamelinck CN, Van Hooijdonk G, Faaij AP. Ethanol from lignocellulosic biomass: techno-economic performance in short-, middle-and long-term. *Biomass and bioenergy*. 2005 Apr 1; 28 (4): 384-410.
- [20] Senabre-Gallego JM, Rosas-Gómez de Salazar J, Santos-Soler G, Santos-Ramírez C, SánchezBarrioluengo M, Salas-Heredia E, et al. Duración del tratamiento con etanercept y razones de discontinuación en una cohorte de pacientes con patología reumática. *Reumatol Clin*. 2011; 7 (6): 385–8.
- [21] Ilyasov IR, Beloborodov VL, Selivanova IA, Terekhov RP. ABTS/PP decolorization assay of antioxidant capacity reaction pathways. *International journal of molecular sciences*. 2020 Jan; 21 (3): 1131.
- [22] Libresco AS, Balantic J, Battenfeld M. Notable books, notable lessons: Putting social studies back in the K-8 curriculum. *ABC-CLIO*; 2017 Sep 21.
- [23] Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. *Ann Rheum Dis*. 2010; 69 (1): 43–7.
- [24] Alves JA, Fialho SC, Morato EF, Castro GR, Zimmermann AF, Ribeiro GG, et al. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. *Rev Bras Reumatol*. 2011; 51 (2): 141–4.
- [25] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018 Jan 5; 359 (6371): 97-103.